Translational programs depend on evidence that remains interpretable in real-world care. That becomes difficult when molecular signals are disconnected from longitudinal clinical history, line of therapy and outcomes context. Teams can generate promising findings yet still lack the patient-level linkage required to validate biomarkers, refine targets and support decision-making in treated populations.
The limitation is rarely data availability. More often, it is the inability to connect clinical and biological information in a way that supports repeatable, defensible evidence generation across programs, modalities and time.
Several challenges recur across translational workflows:
Translational workflows move faster when clinical and biological data are linked at the patient level and structured for longitudinal, cross-modality analysis.
Translational360 is a multimodal oncology dataset combining clinical and biological information, built for organizations advancing innovative therapies. It consists of ConcertAI’s deeply curated clinical data linked at the patient level to biological data from leading genomic laboratories. The dataset connects molecular signals to longitudinal treatment patterns, toxicity and real-world survival.
This patient-level linkage supports translational work where evidence must hold up beyond cross-sectional snapshots, including:
Translational evidence depends on the quality of the data foundation. Four requirements tend to determine whether evidence remains usable after filtering, interpretable across patient journeys and defensible across stakeholders.
Translational360 is supported by longitudinal clinical history from diagnosis to death, deeply validated mortality data and extensive clinical data curation. ConcertAI has invested over 1 million person-hours in clinical curation, supporting consistent definitions and timelines needed for longitudinal interpretation.
This is critical because biology is only interpretable when the clinical timeline behind it is credible and consistent, particularly in treated populations where exposure and timing shape outcomes.
Translational360 draws on over 11 million patient records and includes over 100 curated clinical variables, with data drawn from 18+ discrete EMR systems across all 50 states.
Breadth supports two practical needs. It helps sustain usable cohorts through real-world variability. It also supports higher-resolution cohort construction once clinical and biomarker criteria are applied.
Translational programs vary by modality, tumor type and stage. Translational360 supports multiple molecular diagnostics options and a right-sized approach depending on the program, whether the requirement is WSI, panels, WES or other modalities. Teams can license single-tumor or pan-tumor datasets, supported by licensing or subscription models aligned to scope.
This flexibility reduces the need to rebuild the evidence foundation as program requirements shift.
ConcertAI handles deduplication across clinical records at the patient level, supporting an end-to-end story in one dataset rather than requiring teams to manage multiple genomic partners and repeated reconciliation steps.
Reducing operational overhead accelerates iteration and improves confidence in the provenance of the evidence produced.
Many approaches emphasize one dimension over the other. Some provide clinical depth without sufficient biological resolution. Others provide molecular depth without the longitudinal clinical context needed to interpret treated populations. Translational360 is designed to address that gap by pairing high-fidelity longitudinal clinical history with flexible access to multi-modal biological depth, reducing the need to choose between a strong clinical backbone and best-fit lab inputs.
The practical advantage is evidence that remains decision-relevant across cohorts, modalities and time, with clinical context preserved throughout the analysis.
Translational360 is designed to support biomarker validation, target refinement and program decisions grounded in longitudinal clinical context.
Want to see how Translational360 applies in practice? Read our use case spotlight on a top 20 global biopharmaceutical leader or meet with our team at the 2026 ASCO® Annual Meeting.